Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/10/2879568/0/en/PharmaTher-Announces-Assigned-FDA-Approval-Goal-Date-of-its-Priority-Original-Abbreviated-New-Drug-Application-for-Ketamine.html
https://www.globenewswire.com/news-release/2024/04/18/2865793/0/en/PharmaTher-Provides-Update-of-its-Priority-Original-Abbreviated-New-Drug-Application-for-Ketamine.html
https://www.globenewswire.com/news-release/2024/04/16/2863526/0/en/PharmaTher-Provides-Update-of-its-Priority-Original-Abbreviated-New-Drug-Application-for-Ketamine.html
https://www.globenewswire.com//news-release/2024/02/21/2832853/0/en/PharmaTher-s-Sairiyo-Therapeutics-Inc-Advances-Clinical-Development-of-Patented-Reformulated-Cepharanthine-for-Phase-1-Study-in-Australia.html
https://www.globenewswire.com//news-release/2024/02/12/2827462/0/en/PharmaTher-Provides-Update-of-its-Priority-Original-Abbreviated-New-Drug-Application-for-Ketamine.html
https://www.globenewswire.com//news-release/2024/01/10/2807018/0/en/PharmaTher-Provides-Update-for-Expected-FDA-Approval-of-Ketamine.html
https://www.globenewswire.com//news-release/2023/09/27/2750259/0/en/PharmaTher-Announces-FDA-Acceptance-As-a-Priority-Original-Abbreviated-New-Drug-Application-for-KETARX-Ketamine.html
https://www.globenewswire.com//news-release/2023/09/06/2738258/0/en/PharmaTher-Submits-Priority-Original-Abbreviated-New-Drug-Application-for-KETARX-Ketamine-to-the-FDA.html
https://www.globenewswire.com/news-release/2023/07/18/2706302/0/en/PharmaTher-Announces-Positive-Research-Results-for-PharmaPatch-with-N-N-dimethyltryptamine-DMT-and-Strategic-Investment-into-Sairiyo-Therapeutics.html
https://www.globenewswire.com/news-release/2023/06/12/2686155/0/en/PharmaTher-Holdings-Provides-Corporate-Update.html